Cargando…

Novel Generation of FAP Inhibitor-Based Homodimers for Improved Application in Radiotheranostics

SIMPLE SUMMARY: Radiopharmaceuticals targeting the fibroblast activation protein alpha (FAP) can be used in many different cancer types since FAP is highly expressed in the tumor microenvironment of almost all epithelial cancers. Monomeric radiotracers have shown great potential in molecular imaging...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Marcel, Ballal, Sanjana, Yadav, Madhav Prasad, Bal, Chandrasekhar, Van Rymenant, Yentl, De Loose, Joni, Verhulst, Emile, De Meester, Ingrid, Van Der Veken, Pieter, Roesch, Frank
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047490/ https://www.ncbi.nlm.nih.gov/pubmed/36980775 http://dx.doi.org/10.3390/cancers15061889

Ejemplares similares

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA(5).SA.FAPi and DOTA.SA.FAPi
por: Moon, Euy Sung, et al.
Publicado: (2021)

[(177)Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

In Vitro and In Situ Activity-Based Labeling of Fibroblast Activation Protein with UAMC1110-Derived Probes
por: Van Rymenant, Yentl, et al.
Publicado: (2021)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Radiotheranostic Agents in Hematological Malignancies
por: Caers, Jo, et al.
Publicado: (2022)

Coexistence of Multiple Metastatic Lesions Showing Various Grades of Differentiation in a Single Patient with Neuroendocrine Tumor of Lung as Primary: A Combined Modality Approach of (68)Ga-DOTANOC Positron Emission Tomography/Computed Tomography and (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging
por: Tripathy, Sarthak, et al.
Publicado: (2019)

Efficacy and safety of (225)Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis of (177)Lutetium-labeled Radiopharmaceuticals
por: Arora, Geetanjali, et al.
Publicado: (2017)

Head-to-Head Comparison between [(68)Ga]Ga-DOTA.SA.FAPi and [(18)F]F-FDG PET/CT Imaging in Patients with Breast Cancer
por: Ballal, Sanjana, et al.
Publicado: (2023)

Re-establishment of normal radioactive iodine uptake reference range in the era of universal salt iodization in the Indian population
por: Ballal, Sanjana, et al.
Publicado: (2017)

Clinical Issues Related to Fluid Management during (177)Lu-Peptide Receptor Radionuclide Therapy in Metastatic Neuroendocrine Tumors with Carcinoid Heart Disease
por: Arora, Saurabh, et al.
Publicado: (2018)

[(111)In]In/[(177)Lu]Lu-AAZTA(5)-LM4 SST(2)R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
por: Nock, Berthold A., et al.
Publicado: (2023)

Proline-specific peptidase activities (DPP4, PRCP, FAP and PREP) in plasma of hospitalized COVID-19 patients
por: Bracke, An, et al.
Publicado: (2022)

A long-term retrospective cohort-based risk-benefit analysis of augmenting total cumulative I-131 activity to 37GBq in differentiated thyroid cancer patients with skeletal metastases
por: Kanankulam Velliangiri, Sivasankar, et al.
Publicado: (2023)

Stunning in post (131)I therapy scans after low-dose (131)I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: Critical importance of interval between the two scans
por: Damle, Nishikant A., et al.
Publicado: (2012)

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators
por: Moon, Euy Sung, et al.
Publicado: (2020)

Dual Imaging Gold Nanoplatforms for Targeted Radiotheranostics
por: Silva, Francisco, et al.
Publicado: (2020)

Radiotheranostics Practice in India- Advancing to Precision Oncology
por: Kumar, Rakesh, et al.
Publicado: (2022)

GRPR-targeting radiotheranostics for breast cancer management
por: D’Onofrio, Alice, et al.
Publicado: (2023)

Translating Research for the Radiotheranostics of Nanotargeted (188)Re-Liposome
por: Chang, Chih-Hsien, et al.
Publicado: (2021)

Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging
por: Duan, Heying, et al.
Publicado: (2022)

Editorial: Radiotheranostics: From basic research to clinical application
por: Gareev, Kamil G., et al.
Publicado: (2023)

Long-term outcome of (177)Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment
por: Bal, Chandrasekhar, et al.
Publicado: (2015)

Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application
por: Müller, Cristina, et al.
Publicado: (2018)

ProCPU Is Expressed by (Primary) Human Monocytes and Macrophages and Expression Differs between States of Differentiation and Activation
por: Claesen, Karen, et al.
Publicado: (2023)

Cross‐Isotopic Bioorthogonal Tools as Molecular Twins for Radiotheranostic Applications
por: Rosecker, Veronika, et al.
Publicado: (2019)

Stability Estimation of Gallium Complexes of DOTA Derivatives for Radiotheranostic Applications
por: Suzuki, Hiroyuki, et al.
Publicado: (2022)

Long-term Clinicopathological Features of a Family with Multiple Endocrine Neoplasia Type 2A Caused by C634R RET Gene Mutation
por: Prabhu, Meghana, et al.
Publicado: (2020)

Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?
por: Verhulst, Emile, et al.
Publicado: (2022)

Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions
por: Heidari, Pedram, et al.
Publicado: (2018)

Synthesis and Evaluation of a Dimeric RGD Peptide as a Preliminary Study for Radiotheranostics with Radiohalogens
por: Echigo, Hiroaki, et al.
Publicado: (2021)

Prolyl Carboxypeptidase Mediates the C-Terminal Cleavage of (Pyr)-Apelin-13 in Human Umbilical Vein and Aortic Endothelial Cells
por: De Hert, Emilie, et al.
Publicado: (2021)

Circulating Stromal Cell-Derived Factor 1α Levels in Heart Failure: A Matter of Proper Sampling
por: Baerts, Lesley, et al.
Publicado: (2015)

Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves’ disease: Results of a randomized controlled trial in Indian population
por: Jaiswal, Abhishek Kumar, et al.
Publicado: (2014)

Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases
por: Tansi, Felista L., et al.
Publicado: (2016)

India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to Collaborate
por: Singh, Baljinder, et al.
Publicado: (2023)

The diagnostic accuracy of Sudoscan in TTR-FAP
por: Castro, Jose, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lb09kqh0nf731ok2rjj0e2adcj